Here are four things to know:
1. Baxter intends for Actifuse Flow to be used in the posterolateral spine, pelvis and extremities.
2. The bone graft substitute uses Baxter’s proprietary silicate-substituted technology, which is designed to enhance silicon levels to accelerate bone formation.
3. Actifuse Flow is the newest addition to Baxter’s osteobiologics surgery portfolio, which also includes Actifuse ABX, Actifuse Shape, Actifuse MIS and Altapore.
4. Baxter anticipates Actifuse Flow will be available to U.S. customers by year-end.
More articles on biologics:
Dr. Mark Mikhael studies stem cells for spine surgery – 4 insights
Spine biologics market to exceed $2.6B by 2022: 3 observations
SpinalCyte receives new patent for cartilage repair: 3 insights
